Sodium Tanshinone IIA sulfonate improves post-ischemic angiogenesis in hyperglycemia.

•Sodium tanshinone IIA sulfonate (STS) improves perfusion recovery in experimental peripheral arterial disease (PAD) model with diabetes, but not in PAD models without diabetes.•STS decreases expression of microRNA-133a, a diabetes-induced microRNA, in ischemic muscle tissue and endothelial cells in diabetes.•STS increases angiogenesis and nitric oxide production, and decreases reactive oxygen species in diabetic and hypoxic endothelial cell through microRNA-133a and its target, guanosine triphosphate cyclohydrolase 1.